Physician profile
Mathew Pathrose
NPI 1710258496
$11,688.28
in general payments reported to CMS, 2019-2025
22 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,334 · 2022: $3,869 · 2023: $3,959 · 2024: $1,265 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,963 · Consulting Fee: $2,100 · Education: $343 · Travel and Lodging: $79.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,962.66 |
| Consulting Fee | $2,100.00 |
| Education | $342.87 |
| Travel and Lodging | $79.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,410.65 | 2021-2025 | |
| Incyte Corporation | $951.10 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $937.57 | 2021-2025 | |
| Leo Pharma INC. | $935.20 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $696.74 | 2021-2024 | Dupixent |
| Janssen Biotech, INC. | $683.26 | 2021-2024 | Tremfya |
| Dermavant Sciences, INC. | $519.73 | 2023-2024 | Vtama |
| Pfizer INC. | $435.13 | 2021-2025 | |
| Amgen INC. | $369.39 | 2021-2025 | Krystexxa, Otezla, Otezla |
| Galderma Laboratories, L.P. | $283.05 | 2021-2025 | Nemluvio |
| Genzyme Corporation | $277.24 | 2021-2025 | |
| Ucb, INC. | $254.83 | 2022-2025 | Bimzelx |
| Argenx US, INC. | $227.80 | 2022-2023 | Vyvgart Hytrulo |
| E.R. Squibb & Sons, L.L.C. | $142.06 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $141.98 | 2021-2024 | Taltz, Ebglyss, Olumiant |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $107.06 | 2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $103.22 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Organon LLC | $38.67 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $30.86 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $26.44 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Pathrose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.